Page 15 - Amrx News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Amrx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Amrx Today - Breaking & Trending Today
Wall Street analysts expect Amneal Pharmaceuticals, Inc. (NYSE:AMRX – Get Rating) to report earnings per share (EPS) of $0.19 for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Amneal Pharmaceuticals’ earnings, with estimates ranging from $0.18 to $0.21. Amneal Pharmaceuticals posted earnings per share of $0.25 in the […] ....
Amneal Pharmaceuticals (NYSE:AMRX – Get Rating) issued an update on its FY 2022 earnings guidance on Monday morning. The company provided earnings per share guidance of $0.80-$0.85 for the period, compared to the consensus earnings per share estimate of $0.84. The company issued revenue guidance of $2.15 billion-$2.25 billion, compared to the consensus revenue estimate […] ....
Wall Street analysts forecast that Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Rating) will announce earnings of $0.20 per share for the current quarter, according to Zacks. Four analysts have issued estimates for Amneal Pharmaceuticals’ earnings. The highest EPS estimate is $0.24 and the lowest is $0.18. Amneal Pharmaceuticals reported earnings of $0.25 per share during […] ....
Amneal Pharmaceuticals (NYSE:AMRX – Get Rating) released its earnings results on Wednesday. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by ($0.01), MarketWatch Earnings reports. Amneal Pharmaceuticals had a return on equity of 61.08% and a net margin of 0.68%. The company had revenue of $497.30 […] ....
Amneal Pharmaceuticals (NASDAQ:AMRX – Get Rating) is one of 938 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare Amneal Pharmaceuticals to related businesses based on the strength of its analyst recommendations, dividends, profitability, institutional ownership, risk, valuation and earnings. Profitability This table compares Amneal Pharmaceuticals […] ....